{"id":963864,"date":"2026-05-18T07:04:22","date_gmt":"2026-05-18T11:04:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/"},"modified":"2026-05-18T07:04:22","modified_gmt":"2026-05-18T11:04:22","slug":"regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/","title":{"rendered":"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas"},"content":{"rendered":"
\n

\n The multi-target collaboration combines Regeneron\u2019s industry-leading antibody capabilities with Parabilis\u2019 novel Helicon\u2122 peptide platform\u00a0<\/em>\n <\/p>\n

\n Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties<\/em>\n <\/p>\n

TARRYTOWN, N.Y., May 18, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN<\/strong>) today announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis\u2019 Helicon\u2122 peptide platform, with a particular focus on Antibody-Helicon\u2122 Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically \u201cundruggable\u201d targets.\u00a0\u00a0 <\/p>\n

Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets, including flat surfaces not well suited to traditional small molecule binding. The collaboration is designed to explore the use of Helicons both as stand-alone therapies and as part of AHCs.<\/p>\n

\u201cThis collaboration reflects Regeneron\u2019s approach of advancing cutting-edge and diversified science to produce a robust portfolio of innovative medicines for patients in need,\u201d said George D. Yancopoulos, M.D., Ph.D., Board\u00a0co-Chair, President and Chief Scientific Officer of Regeneron. \u201cIn addition to the potential of Helicons to address previously undruggable targets, the collaboration\u2019s intent to couple Helicons to our VelocImmune<\/em>\u00ae derived-antibodies so as to precisely deliver them to cells of interest represents an exciting new approach with the potential to create an entirely new therapeutic class that can span multiple therapeutic areas.\u201d<\/p>\n

Antibody\u2013drug conjugates traditionally use antibodies to selectively deliver drug payloads into target cells to drive cell death from within. The AHCs envisioned by this collaboration are underpinned by the same delivery principle: pairing antibody-targeted cell access with Helicon payloads designed to selectively modulate specific intracellular proteins, including some long considered undruggable.<\/p>\n

Under the terms of the agreement, Parabilis is to receive $125 million from Regeneron in the form of a $50 million upfront payment and a commitment to invest $75 million in Parabilis\u2019 next equity financing, subject to certain conditions. Parabilis is also eligible to receive milestone payments for development, regulatory and commercial milestones, as well as tiered royalties up to the low double-digits on future net sales of any approved medicines resulting from the collaboration. With five initial targets, the agreement provides the potential for up to approximately $2.2 billion in total milestone payments to Parabilis. Under the terms of the agreement, additional targets may be pursued upon additional option payments from Regeneron.<\/p>\n

The agreement provides for the parties to collaborate to discover new Helicons and AHCs, which Regeneron will then be responsible for advancing through development, manufacturing and worldwide commercialization.<\/p>\n

\n About Regeneron<\/strong>
\n
Regeneron\u00a0is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases.\u00a0Founded and led by physician-scientists,\u00a0Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in\u00a0Regeneron’s laboratories.\u00a0Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.<\/p>\n

Regeneron\u00a0pushes the boundaries of scientific discovery and accelerates drug development using its proprietary technologies, such as\u00a0VelociSuite<\/em>\u00ae, which produces optimized fully human antibodies and new classes of bispecific antibodies.\u00a0Regeneron\u00a0is shaping the next frontier of medicine with data-powered insights from the\u00a0Regeneron\u00a0Genetics Center\u00ae\u202fand pioneering genetic medicine platforms, enabling\u00a0Regeneron\u00a0to identify innovative targets and complementary approaches to potentially treat or cure diseases.<\/p>\n

For more information, please visit www.regeneron.com<\/a>\u00a0or follow Regeneron on LinkedIn<\/a>, Instagram<\/a>, Facebook<\/a>, YouTube<\/a>, or X<\/a>.<\/p>\n

\n Regeneron Forward-Looking Statements and Use of Digital Media<\/strong>\u00a0
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (\u201cRegeneron\u201d or the \u201cCompany\u201d), and actual events or results may differ materially from these forward-looking statements. Words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and\/or its collaborators or licensees (collectively, \u201cRegeneron\u2019s Products\u201d) and product candidates being developed by Regeneron and\/or its collaborators or licensees (collectively, \u201cRegeneron\u2019s Product Candidates\u201d) and research and clinical programs now underway or planned, such as the planned research programs in collaboration with Parabilis Medicines (\u201cParabilis\u201d) to advance Antibody-Helicon\u2122 Conjugates as discussed in this press release; the potential for any license, collaboration, or supply agreement, including Regeneron\u2019s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) as well as Regeneron\u2019s collaboration with\u00a0Parabilis\u00a0discussed in this press release, to be cancelled or terminated; the extent to which the results from the research and development programs conducted by Regeneron and\/or its collaborators or licensees (including those to be conducted as part of the collaboration with\u00a0Parabilis\u00a0discussed in this press release)\u00a0may be replicated in other studies and\/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the potential of combining for therapeutic purposes Regeneron\u2019s expertise in human genetics and antibody discovery with Parabilis\u2019 Helicon<\/em>TM<\/em><\/sup> peptide platform; uncertainty of the utilization, market acceptance, and commercial success of Regeneron\u2019s Products and Regeneron\u2019s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on any of the foregoing;\u00a0 the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron\u2019s Product Candidates and new indications for Regeneron\u2019s Products; the ability of Regeneron\u2019s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron\u2019s Products and Regeneron\u2019s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron\u2019s Products and Regeneron\u2019s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron\u2019s Products and Regeneron\u2019s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron\u2019s ability to continue to develop or commercialize Regeneron\u2019s Products and Regeneron\u2019s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron\u2019s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron\u2019s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron\u2019s pricing strategy, including in connection with Regeneron\u2019s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron\u2019s Products and Regeneron\u2019s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and\/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA<\/em>\u00ae<\/em><\/sup> (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron\u2019s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron\u2019s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended March 31, 2026. Any forward-looking statements are made based on management\u2019s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.<\/em><\/p>\n

\n Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https:\/\/investor.regeneron.com) and its LinkedIn page (https:\/\/www.linkedin.com\/company\/regeneron-pharmaceuticals<\/a>).<\/em>\n <\/p>\n

\n Media Contact for Regeneron <\/strong>
\n
Alexandra Bowie
Alexandra.bowie@regeneron.com<\/a>\u00a0<\/p>\n

\n Investor Contact for Regeneron<\/strong>
\n
Vesna Tosic
Vesna.tosic@regeneron.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The multi-target collaboration combines Regeneron\u2019s industry-leading antibody capabilities with Parabilis\u2019 novel Helicon\u2122 peptide platform\u00a0 Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y., May 18, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis\u2019 Helicon\u2122 peptide platform, with a particular focus on Antibody-Helicon\u2122 Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically \u201cundruggable\u201d targets.\u00a0\u00a0 Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets, including flat surfaces not well suited … <\/p>\n

Continue reading “Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963864","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRegeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The multi-target collaboration combines Regeneron\u2019s industry-leading antibody capabilities with Parabilis\u2019 novel Helicon\u2122 peptide platform\u00a0 Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y., May 18, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis\u2019 Helicon\u2122 peptide platform, with a particular focus on Antibody-Helicon\u2122 Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically \u201cundruggable\u201d targets.\u00a0\u00a0 Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets, including flat surfaces not well suited … Continue reading "Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T11:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas\",\"datePublished\":\"2026-05-18T11:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/\"},\"wordCount\":1577,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/\",\"name\":\"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=\",\"datePublished\":\"2026-05-18T11:04:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/","og_locale":"en_US","og_type":"article","og_title":"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas - Market Newsdesk","og_description":"The multi-target collaboration combines Regeneron\u2019s industry-leading antibody capabilities with Parabilis\u2019 novel Helicon\u2122 peptide platform\u00a0 Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y., May 18, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis\u2019 Helicon\u2122 peptide platform, with a particular focus on Antibody-Helicon\u2122 Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically \u201cundruggable\u201d targets.\u00a0\u00a0 Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets, including flat surfaces not well suited … Continue reading \"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-18T11:04:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas","datePublished":"2026-05-18T11:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/"},"wordCount":1577,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/","name":"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=","datePublished":"2026-05-18T11:04:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTgyMSM3NjA3NjQwIzIwMDYyNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon\u2122 Conjugates Across Multiple Therapeutic Areas"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963864"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963864\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}